US20050181053A1 - Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures - Google Patents

Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures Download PDF

Info

Publication number
US20050181053A1
US20050181053A1 US11096457 US9645705A US2005181053A1 US 20050181053 A1 US20050181053 A1 US 20050181053A1 US 11096457 US11096457 US 11096457 US 9645705 A US9645705 A US 9645705A US 2005181053 A1 US2005181053 A1 US 2005181053A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
coating layer
cellulose
composition
mg
poly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11096457
Inventor
Gregory Dittmar
Joseph Amante
Tony Cronk
Daniel Newby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Pharmaceuticals International Ltd
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891Coated capsules; Multilayered drug free capsule shells

Abstract

The present invention relates to a pharmaceutical composition in a solid unit dosage form for oral administration in a human or lower animal comprising: a. a safe and effective amount of a therapeutically active agent; b. an inner coating layer selected from the group consisting of poly(methacrylic acid, methyl methacrylate) 1:2, poly(methacrylic acid, methyl methacrylate) 1:1, and mixtures thereof; and c. an outer coating layer comprising an enteric polymer or film coating material; wherein the inner coating layer is not the same as the outer coating layer; wherein if the inner coating layer is poly(methacrylic acid, methyl methacrylate) 1:1 then the outer coating layer is not poly(methacrylic acid, methyl methacrylate) 1:2 or is not a mixture of poly(methacrylic acid, methyl methacrylate) 1:1 and poly(methacrylic acid, methyl methacrylate) 1:2; and wherein the inner coating layer and the outer coating layer do not contain any therapeutically active agent. This invention further relates to a method of maintaining the desired site of delivery of a therapeutic agent in the gastrointestinal tract by administering the above compositions to a human or lower animal.

Description

    CROSS REFERENCE TO RELATED APPLICATION
  • This application claims the benefit of U.S. Provisional Application No. 60/252,122, filed Nov. 20, 2000.
  • TECHNICAL FIELD
  • The present invention relates to novel unit dosage forms comprising therapeutic agents with improved resistance to coating fractures during processing, manufacturing or packaging.
  • BACKGROUND OF THE INVENTION
  • A number of prior art references teaches the advantages of delivery of therapeutic agents to the lower part of the gastrointestinal tract, especially the large intestine or the colon. These reference illustrate the difficulty of formulating dosage forms that will achieve this delivery benefit. For example, U.S. Pat. Nos. 5,541,170 and 5,541,171, Rhodes et al., both issued Jul. 30, 1996, discuss the delivery of pharmacologically active agents, especially 5-aminosalicylic acid, to the large intestine for the treatment of colonic or rectal disorders. U.S. Pat. No. 5,686,105, Kelm et al., issued Nov. 11, 1997, teaches colonic delivery of therapeutic agents wherein the dosage form comprises a coating system with at least one inner coating layer and one outer coating layer. The inner coating layer is an enteric polymer that begins to dissolve in an aqueous media at a pH between about 5 to about 6.3, and the outer coating layer is an enteric polymer that begins to dissolve in an aqueous media at a pH of between about 6.8 to 7.2. U.S. Pat. No. 5,171,580, Iamartino et al., issued Dec. 15, 1992, teaches pharmaceutical preparations containing an active ingredient to be released in the lower part of the gastrointestinal tract, the large intestine and especially the colon, consisting of a core with the active, the core being coated with three protective layers at different solubilities. This reference focuses on providing more specific and reliable release of a therapeutic active agent to the lower part of the gastrointestinal tract, especially the colon, achieved with the three protection layers, as well as the benefits of having a selective effect in the colon. Other prior art references also focus on the benefits of delivering therapeutic agents to the colon. These references include U.S. Pat. No. 5,686,106, Kelm et al., issued Nov. 11, 1997; U.S. Pat. No. 5,914,132, Kelm et al, issued Jun. 22, 1999; U.S. Pat. No. 4,910,021. Davis et al, issued Mar. 20, 1990: U.S. Pat. No. 4,432,966, Zeitoun et al., issued Feb. 21, 1984; U.S. Pat. No. 5,654,004, Okayama et al., issued August 5, 1997; U.S. Pat. No. 5,900,252, Calcanchi et al., issued May 4, 1999; U.S. Pat. No. 5,482,718, Shah et al, issued Jan. 9, 1996; U.S. Pat. No. 5,316,772, Jurgens et al., issued May 31, 1994; EP 225,189, Davies, et al, published Jun. 10, 1987; and Khan et al., Drug Development and Industrial Pharmacy, 26(5), 549-554 (2000).
  • None of the above prior art references, however, discusses the problem or possibility of coating fractures that may occur during processing, manufacturing, or packaging of the oral unit dosage form. Coating fractures may cause unreliable or inconsistent delivery or release of the therapeutic agent to the desired region of the gastrointestinal tract. These fractures may be associated with premature rupture or release of the unit dosage forms. Indeed, coating fractures may especially be problematic for larger than average size unit dosage forms or heavier unit dosage forms resulting from using larger dosages/levels of the therapeutic active.
  • The present invention, therefore, relates to solid unit dosage forms for oral administration in humans or lower animals which minimizes the impact or negative effects of coating fractures, especially for larger or heavier unit dosage forms. By reducing these negative effects, these compositions maintain the desired site of delivery of the therapeutic agents in the gastrointestinal tract.
  • SUMMARY OF THE INVENTION
  • The present invention relates to a pharmaceutical composition in a solid unit dosage form for oral administration in a human or lower animal comprising:
      • a. a safe and effective amount of a therapeutically active agent;
      • b. an inner coating layer selected from the group consisting of poly(methacrylic acid, methyl methacrylate) 1:2, poly(methacrylic acid, methyl methacrylate) 1:1, and mixtures thereof; and
      • c. an outer coating layer comprising an enteric polymer or film coating material;
        wherein the inner coating layer is not the same as the outer coating layer; wherein if the inner coating layer is poly(methacrylic acid, methyl methacrylate) 1:1 then the outer coating layer is not poly(methacrylic acid, methyl methacrylate) 1:2 or is not a mixture of poly(methacrylic acid, methyl methacrylate) 1:1 and poly(methacrylic acid, methyl methacrylate) 1:2; and wherein the inner coating layer and the outer coating layer contain no therapeutically active agent.
  • In another embodiment the present invention relates to a pharmaceutical composition in a solid unit dosage form for oral administration in a human or lower animal comprising:
      • a. a safe and effective amount of a therapeutically active agent;
      • b. an inner coating layer comprising poly(methacrylic acid, methyl methacrylate) 1:2: and
      • c. an outer coating layer comprising an enteric polymer or film coating material;
        wherein the inner coating layer is not the same as the outer layer coating. This invention further relates to a method of maintaining the desired site of delivery of a therapeutic agent in the gastrointestinal tract by reducing the impact of coating fractures, through administering the above compositions to a human or lower animal.
    DETAILED DESCRIPTION OF THE INVENTION
  • The phrase “safe and effective amount”, as used herein, means an amount of therapeutically active agent or other component of the present compositions, high enough to provide a significant positive modification of the condition to be treated, but low enough to avoid serious side effects (at a reasonable benefit/risk ratio), within the scope of sound medical judgment. A safe and effective amount of therapeutically active agent or other component of the present compositions, will vary with the particular condition being treated, the age and physical condition of the patient being treated, the severity of the condition, the duration of the treatment, the nature of concurrent therapy, the agent selected and like factors.
  • Therapeutically Active Agent
  • The methods and compositions of the present invention comprise a safe and effective amount of the therapeutically active agent. In one embodiment the therapeutic agents suitable for incorporation into dosage forms of the present invention are those for which treatment of the colon is therapeutically advantageous. These include therapeutic agents useful for the treatment of diseases of the colon such as constipation, diarrhea, irritable bowel syndrome (IBS), Crohn's disease, colitis, ulcerative colitis, carcinomas, idiopathic protitis, infection in which systemic absorption of the therapeutic agent is neither required or desired, and other diseases or disorders of the colon or rectum. These include actives for constipation and laxatives such as picosulfate and sennasides, anti-diarrheals such as loperamide, nonsteroidal anti-inflammatory drugs such as salicylates, indomethacin, ibuprofen, flurbiprofen, naproxen, piroxicam 5-amino salicylic acid (or pharmaceutically acceptable salts or esters thereof), balsalazide as well as agents disclosed in U.S. Pat. No. 4,412,992, Chan, issued Nov. 1, 1983, as well as NSAIDS disclosed in U.S. Pat. No. 4,552,899, Sunshine et al., issued Nov. 12, 1985, steriods such as hydrocortisone, prednisone, prednisolone, prednisolone phosphate, prednisolone metasulpho-benzoate sodium, prednisolone sodium phosphate, beclomethasone dipropionate and beclomethasone valerate, glucocorticoids such as dextramethazone, antimicrobials or antiparasitic agents, (especially those effective against anaerobic microbes such as methotrexate), 5-aminosalicylic compounds, 4-aminosalicylic compounds, sulfasalazine, benzalazine, erythromycin, chloroguine, iodochlorhydroxyquin, disodohydroxyquin, neomycin and tetracyclines, immunosupressants such as cyclosporine A, chemotherapeutics for treatment of carcinomas, gastointestinal stimulants and prokinetic agents such as cisapride, peppermint oil and other carminative essential oils, actives for the removal of excess bile acids such as cholestyramine. The above references are herein incorporated by reference in their entirety.
  • Certain therapeutic agents, particularly peptides and proteins, are subject to lumenal degradation in the stomach and small intestine. The colon may be a preferable site of absorption for such compounds since lumenal enzymatic activity is less in the colon (M. Mackay and E. Tomlinson, in Colonic Drug Absorption and Metabolism, P. R. Bieck, ed., Marcel Dekker, Inc., New York, Basel, Hong Kong, 137-158 (1993)). Peptides and proteins that may exhibit improved systemic bioavailability benefit when released in the colon include calcitonin, insulin, and human growth hormone. In certain cases, the peptide or protein may be formulated with a system than enhances the absorption of the macromolecule (M. Mackay and E. Tomlinson, in Colonic Drug Absorption and Metabolism, P. R. Bieck, ed., Marcel Dekker, Inc., New York, Basel, Hong Kong, 137-158 (1993)).
  • The therapeutically active agents are present in the solid dosage forms in suitable unit dosage amounts. These amounts will be known by those skilled in the art. In one embodiment the active agent is 5-amino salicylic acid or pharmaceutically acceptable salts or esters thereof at a dosage range of from about 400 mg to about 1.5 grams per tablet, in another embodiment is from about 700 mg to about 900 mg per tablet.
  • The therapeutically active agent may be incorporated into one of the several substrates described herein in a manner consistent with the physical chemical properties of the drug and its pharmacodynamics, using techniques known to those skilled in the art.
  • The Inner and Outer Coating Layers
  • In one embodiment the coating layers of the present invention do not contain any therapeutically active agent of the present invention. In addition, the “coating layers” described herein refer to completely encasing or coating all of the solid unit dosage form (does not include coated microcrystal spheres, coated pellets, coated beads, coated microparticles or particles, or coated granules, of the therapeutically active agent).
  • Inner Coating Layer
  • The inner coating layer is selected from the group consisting of poly(methacrylic acid, methyl methacrylate) 1:2, poly(methacrylic acid, methyl methacrylate) 1:1, and mixtures thereof. Generally the inner coating layer is selected based on the preferred delivery site desired and is applied to the core of the unit dosage form to achieve a minimum coating thickness from about 20 μm to about 120 μm. The coating thickness depends on the actual size of the unit dosage form, but in one embodiment the minimum coating thickness of the inner coating layer is from about 20 μm to about 50 μm.
  • In one embodiment the inner coating layer comprises poly (methacrylic acid, methyl methacrylate) 1:2 (Eudragit® S), or other enteric polymer material which has the same pH release characteristics in aqueous media as Eudragit® S. Eudragit® S, an anionic copolymer derived from methacrylic acid and methyl methacrylate, with a ratio of free carboxyl groups to the ester groups of approximately 1:2, and a mean molecular weight of approximately 135,000, from Rohm Tech. In one embodiment the inner coating layer is any other polymer with the same aqueous pH release charcteristics as Eudragit® S.
  • Outer Coating Layer
  • The outer coating layer comprises an enteric polymer or film coating material, wherein the inner coating layer is not the same as the outer coating layer. Generally, if the inner coating layer is poly(methacrylic acid, methyl methacrylate) 1:1 (Eudragit® L) then the outer coating layer is not poly(methacrylic acid, methyl methacrylate) 1:2 (Eudragit® S) or is not a mixture of poly(methacrylic acid, methyl methacrylate) 1:1 and poly(methacrylic acid, methyl methacrylate) 1:2. The outer coating material can be any coating material that protects the inner coating layer from fractures during handling and that dissolves or is removed in the gastrointestinal tract prior to the inner coating layer. The outer coating layer is either a single coating or multiple coatings of either an enteric polymer material or film coating material. In another embodiment the unit dosage form has a single outer coating layer. In another embodiment the outer coating layer is an anionic copolymer. In one embodiment the outer coating cannot comprise an enteric polymer or mixtures thereof with the same pH of release in aqueous media as Eudragit® S. If the inner coating is poly(methacrylic acid, methyl methacrylate 1:2, then the outer coating layer can only comprise poly(methacrylic acid, methyl methacrylate 1:2 (Eudragit® S) if it is mixed with another enteric polymer or film coating material such that the pH of release, in aqueous media, for the mixture is less than the pH of release (aqueous media) for poly(methacrylic acid, methyl methacrylate 1:2 (Eudragit® S) alone.
  • In another embodiment the outer coating layer is an enteric polymer material that begins to dissolve in an aqueous media at a pH of less than about 7, in another embodiment at a pH of less than about 6.8. Generally the outer coating layer is applied to the core of the unit dosage form to achieve a minimum thickness of from about 10 μm to about 200 μm, in another embodiment is from about 30 μm to about 150 μm.
  • In one embodiment the outer coating layer is selected from the group consisting of film coatings, cellulose derivatives, cellulose ethers, methyl cellulose, ethylcellulose, carboxymethylcellulose, carboxymethylethylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, low viscosity hydroxypropyl cellulose, low viscosity hydroxypropyl methylcellulose, wax or wax like substance, such as camauba wax, fatty alcohols, hydrogenated vegetable oils, zein, shellac, sucrose, Arabic gum, polyethylene glycol, polyvinylpyrolidone, gelatin, sodium alginate, dextrin, psyllium husk powder, polymethacrylates, anionic polymethacrylates, poly(methacrylic acid, methyl methacrylate) 1:1, mixtures of poly(methacrylic acid, methyl methacrylate) 1:2 and poly(methacrylic acid, methyl methacrylate) 1:1, cellulose acetate phthalate, cellulose acetate trimelliate, hydroxypropyl methylcellulose phthalate (HPMCP), cellulose propionate phthalate, cellulose acetate maleate, polyvinyl alcohol phthalate, hydroxypropyl methylcellulose acetate succinate (HPMCAS), hydroxypropyl methylcellulose hexahydrophthalate, polyvinyl acetate phthalate, poly(methacrylic acid, ethyl acrylate) 1:1, and compatible mixtures thereof.
  • In another embodiment the outer coating layer is selected from the group consisting of cellulose derivatives, cellulose ethers, methyl cellulose, ethylcellulose, carboxymethylcellulose, carboxymethylethylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, low viscosity hydroxypropyl cellulose, low viscosity hydroxypropyl methylcellulose, fatty alcohols, hydrogenated vegetable oils, zein, shellac, sucrose, Arabic gum, polyethylene glycol, polyvinylpyrolidone, gelatin, sodium alginate, dextrin, psyllium husk powder, polymethacrylates, anionic polymethacrylates, poly(methacrylic acid, methyl methacrylate) 1:1, mixtures of poly(methacrylic acid, methyl methacrylate) 1:2 and poly(methacrylic acid, methyl methacrylate) 1:1, cellulose acetate phthalate, cellulose acetate trimelliate, hydroxypropyl methylcellulose phthalate (HPMCP), cellulose propionate phthalate, cellulose acetate maleate, polyvinyl alcohol phthalate, hydroxypropyl methylcellulose acetate succinate (HPMCAS), hydroxypropyl methylcellulose hexahydrophthalate, polyvinyl acetate phthalate, poly(methacrylic acid, ethyl acrylate) 1:1, and compatible mixtures thereof.
  • In another embodiment the outer coating layer is selected from the group consisting of anionic polymethacrylates, poly(methacrylic acid, methyl methacrvlate) 1:1, mixtures of poly(methacrylic acid, methyl methacrylate) 1:2 and poly(methacrylic acid, methyl methacrylate) 1:1, cellulose acetate phthalate, cellulose acetate trimelliate, hydroxypropyl methylcellulose phthalate (HPMCP), cellulose propionate phthalate, cellulose acetate maleate, polyvinyl alcohol phthalate, hydroxypropyl methylcellulose acetate succinate (HPMCAS), hydroxypropyl methylcellulose hexahydrophthalate, polyvinyl acetate phthalate, poly(methacrylic acid, ethyl acrylate) 1:1, and compatible mixtures thereof.
  • In another embodiment the outer coating layer is a single layer of a mixture of poly(methacrylic acid, methyl methacrylate) 1:1 (Eudragit® L) and poly(methacrylic acid, methyl methacrylate) 1:2 (Eudragit® S) in a ratio of about 1:10 to about 1:10, preferably about 1:5 to about 1:3 more preferably about 2:3. The coating thickness depends on the actual size of the unit dosage form, but in one embodiment the minimum coating thickness of the outer coating layer is from about 10 μm to about 50 μm, in another embodiment is from about 20 μm to about 40 μm.
  • In another embodiment the outer coating layer is a single coating of an enteric polymer that begins to dissolve in aqueous media at a pH between about 5 to about 6.3, in another embodiment at a pH between about 5 to about 6, in even another embodiment at a pH between about 5 to about 5.5.
  • In one embodiment, the function of the outer coating layer is to prevent or minimize fractures of the inner coating layer during formulation processing, manufacturing, and packaging, and the function of the inner coating layer is to maintain the desired point of release of the therapeutic active agent in the gastrointestinal tract. For example if the inner coating is poly(methacrylic acid, methyl methacrylate) 1:2 (Eudragit® S), the present invention maintains the desired point of release, as described, for example, in U.S. Pat. Nos. 5,541,170 and 5,541,171, Rhodes et al., which are incorporated herein by reference in their entirety.
  • In one embodiment the total coating thickness (both the inner and outer coating layers together) is from about 5 mg/cm2 to about 40 mg/cm2, in another embodiment is from about 10 mg/cm2 to about 15 mg/cm2.
  • Specific examples of the outer coating layer follow.
    • Eudragit® L, is an anionic copolymer derived from methacrylic acid and methyl methacrylate, with a ratio of free carboxyl groups to the ester groups of approximately 1:1, and a mean molecular weight of approximately 135,000, from Rohm Tech;
    • Eudragit® L 30 D, is an aqueous acrylic resin dispersion, an anionic copolymer derived from methacrylic acid and ethyl acrylate with a ratio of free carboxyl groups to the ester groups of approximately 1:1, and a mean molecular weight of approximately 250,000; (it is supplied as an aqueous dispersion containing 30% w/w of dry lacquer substance);
    • Eudragit® L 100-55, is an anionic copolymer derived from methacrylic acid and ethyl acrylate, with a ratio of free carboxyl groups to the ester groups of approximately 1:1, and a mean molecular weight greater than about 100,000;
    • cellulose acetate phthalate or CAP®, available from Eastman Chemical;
    • cellulose acetate trimelliate, CAT® available from Eastman Chemical;
    • hydroxypropyl methylcellulose phthalate (USP/NF type 220824) HPMCP 50® and (USP/NF type 200731) HPMCP 55® available from Shin Etsu Chemical;
    • polyvinyl acetate phthalate, PVAP®, available from Colorcon;
    • hydroxypropyl methylcellulose acetate succinate, HPMCAS®, available from Shin Etsu Chemical; hydroxypropylcellulose, Klucel®.
  • To enhance the elasticity of the coating materials, preferably the coating material of the present invention also comprises a plasticizer. Appropriate plasticizers include polyethylene glycols, propylene glycols, 1,2-propylene glycol, dibutyl phthalate, diethyl phthalate, tributyl citrate, tributyrin, butyl phthalyl butyl glycolate (Santicizer® B-16, from Monsanto, St. Louis, Mo.), triacetin, castor oil and citric acid esters; in another embodiment the plasitcizer is dibutyl phthalate, tributyl citrate, or triethyl citrate. These plasticizers are present in an amount to facilitate the coating process and to obtain an even coating film with enhanced physical stability. Generally the coating material comprises from about 0% to about 50% of a plasticizer, preferably from about 2% to about 25% by weight, more preferably from about 10% to about 20% by weight of the enteric polymer.
  • In addition, to facilitate the coating process, the coating material may also comprise inert solid particulates. Preferred inert solid particulates include talc and titanium dioxide.
  • The selections of optional plasticizer, optional inert solid particulate, and levels thereof, coating formulation type (solvent, ammoniated aqueous solution, or aqueous dispersion), and process are based upon the specific enteric polymer or film coatings used and the type of dosage form used according to criteria known to those skilled in the art. The solvent for the coating layers may be organic or aqueous. In one embodiment the coating layer is obtained via the use of an aqueous dispersion of the coating material.
  • The Dosage Form and Method of Making the Dosage Form
  • A safe and effective amount of therapeutically active agent is incorporated into a solid unit dosage form. The term “solid unit dosage form” means any dosage form, preferably non-liquid, intended to be swallowed and having a sufficiently defined form to be coated. Solid unit dosage forms may be selected from the group consisting of a hard or soft capsule or a compressed tablet. In one embodiment the solid dosage forms of the present invention are selected from the group consisting of soft gelatin capsules; hard gelatin capsules; and compressed tablets of any size or shape. In one embodiment the unit dosage form of the present invention comprises a unit dosage form from about 550 mg to about 1.5 gram total weight, in another embodiment from about 600 mg to about 1.2 grams total weight, and in even another embodiment from about 750 mg to about 1 gram total weight.
  • In one embodiment the unit dosage form is a spherical or elliptical soft elastic gelatin capsule. The soft elastic gelatin capsule is filled with therapeutically active agent suspended in a suitable vehicle compatible with the soft gelatin capsule.
  • In still another embodiment the unit dosage form is a hard capsule (i.e. starch or gelatin hard. capsule), for example a starch capsule such as Capill® from Capsulgel (Greenwood, S.C.) in which the length of the long axis of the capsule is less than about 10 mm and not more than about 1.5 times greater than the short axis diameter of the capsule. The capsule may be filled with a solid form of therapeutically active agent as described above, or alternatively with therapeutically active agent dissolved or suspended in a suitable vehicle compatible with the capsule wall.
  • In another embodiment the unit dosage form is a compressed spherical or elliptical tablet. The tablet is comprised of a solid form of therapeutically active agent and is compressed using conventional equipment and processes.
  • In addition to the therapeutically active agent the compositions of this invention also generally comprise pharmaceutiacally acceptable excipients. As used herein, “excipient” means one or more compatible solid or liquid filler diluents or encapsulating substances which are suitable for administration to a subject. The term “compatible”, as used herein, means that the components of the composition are capable of being commingled with the active agent, and with each other, in a manner such that there is no interaction which would substantially reduce the pharmaceutical efficacy of the composition under ordinary use situations. Pharmaceutically-accepted excipents must, of course, be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the subject being treated. Excipients may act to facilitate incorporation of the therapeutically active agent into the dosage form, modify the release of the therapeutically active agent from the dosage form, stabilize the therapeutically active agent. or enhance absorption of the therapeutically active agent. Excipients should be safe for their intended use at the levels employed in the formulation. The formulation of therapeutically active agent and excipients is selected according to criteria well known to those skilled in the art to achieve the desired release rate, stability, absorption, and to facilitate the dosage form manufacture.
  • Some examples of pharmaceutically-acceptable excipients or components thereof are sugars, such as lactose, glucose, and sucrose; starches, such as cornstarch, potato starch, and sodium starch glycolate at a level of about 1% to about 8% by weight, in another embodiment from about 2% to about 4% by weight; cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, cellulose acetate; powdered tragacanth; malt; gelatin; talc; solid lubricants, such as stearic acid, magnesium stearate; or calcium sulfate; vegetable oils, such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil, and oil of theobroma; polyols such as propylene glycol, glycerin, sorbitol, mannitol, and polyethylene glycol; alginic acid; emulsifiers, such as the Tweens®; wetting agents such as sodium lauryl sulfate; coloring agents; flavoring agents; excipients; tableting agents; stabilizers; antioxidants; preservatives; pyrogen-free water; isotonic saline; and phosphate buffer solutions. Excipients are described in Remington's Pharmaceutical Sciences, Mack Publishing Co. (19th edit. 1995); Modern Pharmaceutics, Vol. 7, Chapters 9 & 10, Banker & Rhodes (1979); Lieberman, et al, Pharmaceutical Dosage Forms: Tablets (1981); and Ansel, Introduction to Pharmaceutical Dosage Forms, 2d (1976). Their selection will depend on secondary considerations like taste, cost, and shelf stability, etc. which are not critical for the purposes of the subject invention, and can be made without difficulty by those skilled in the art.
  • In one embodiment all of the dosage forms of the present invention are uniform in size prior to coating with the coating layers. The uniform size allows for uniform coating thickness and more uniform dissolution of the coating layers.
  • Enteric polymers are generally applied onto the unit dosage forms as solutions in organic or aqueous solvents. The solvents commonly employed as vehicles are water, methylene chloride, ethanol, methanol, isopropyl alcohol, acetone, ethyl acetate and combinations thereof. The choice of the solvent is based primarily on the solubility of the polymer, ease of evaporation, and viscosity of the solution.
  • Some polymers are also available as aqueous systems. These include Eudragit® L30D (methacrylic acid-ethyl acrylate ester copolymer marketed by Rohm-Haas GmBH, West Germany); Aquateric® (cellulose acetate phthalate-containing product marketed by FMC Corporation, Philadelphia, Pa.); and Coateric® (a polyvinyl acetate phthalate based product marketed by Colorcon, Inc., West Point, Pa.). Unlike organic solutions, these aqueous-based systems can be prepared at high concentration without encountering high viscosity. Also, these aqueous systems do not have the problems associated with the organic systems such as flammability, toxicity of the residual solvent in the dosage form, etc.
  • Coating can be achieved by methods known to one skilled in the art such as by using fluidized bed equipment, perforated pans, a regular pharmaceutical pan, compression coating, continuous or short spray methods, or by drenching. For example, a plasticized dispersion of coating polymer may be applied onto the tablet core comprising the therapeutic active agent by spraying using any suitable spray equipment known in the art. In one embodiment the solid unit dosage forms are coated by continuous spray methods. In one embodiment the outer coating layer is applied after the inner coating layer but before the inner coating layer is dried and/or cured. In yet another embodiment the outer coating layer is applied immediately, e.g. within seconds, after the inner coating layer is applied. If a shiny finish coat is desired on the solid dosage forms of the present invention, a small quantity of polyethylene glycol can be applied to the finished dosage form.
  • The following non-limiting examples provide typical formulations for compositions of the present invention.
  • EXAMPLE 1
  • A wet granulation of 5-ASA (active ingredient), lactose, and povidone is blended with talc, magnesium stearate, sodium starch glycolate, and colloidal silicon dioxide. The blend is compressed into approximately 1034 mg tablets containing 800 mg of the active ingredient on a standard pharmaceutical rotary tablet press.
  • An inner layer of an EUDRAGIT® S coating of 9.2 mg/cm2 dried coating (i.e. about 62 microns) is applied to the core tablets first by pouring a portion of the coating formula without pigments and then by spraying coating onto the tablets. The coating suspension sprayed onto the tablets contains approximately 62% by weight on a dry basis of Eudragit®0 S and is based in isopropyl alcohol and acetone with dibutylphthalate as the acting plasticizer.
  • An outer coating is either applied immediately following the application of the inner coating or once the inner coating has cured. The outer coating layer is sprayed onto the tablets to achieve of 4.1 mg/cm2 dried coating (i.e. about 28 microns). This coating suspension contains approximately 61% by weight on a dry basis of EUDRAGIT® S and L in a ratio of 3:2. It is based in isopropyl alcohol and acetone with dibutylphthalate as the acting plasticizer.
  • EXAMPLE 2
  • A wet granulation of 5-ASA (active ingredient), lactose, and povidone is blended with talc, magnesium stearate, sodium starch glycolate, and colloidal silicon dioxide. The blend is compressed into approximately 1570 mg tablets containing 1200 mg of the active ingredient on a standard pharmaceutical rotary tablet press.
  • An inner layer of an EUDRAGIT® S and L mixture of 8.8 mg/cm2 dried coating (i.e. about 60 microns) is applied to the core tablets first by pouring a portion of the coating formula without pigments and then by spraying coating onto the tablets. The coating suspension sprayed onto the tablets contains approximately 61% by weight on a dry basis of Eudragit® S and L in a ratio of 3:2 and is based in isopropyl alcohol and acetone with dibutylphthalate as the acting plasticizer.
  • An outer coating is applied immediately following the application of the inner coating or once the inner coating has cured. The outer coating layer is sprayed onto the tablets to achieve of 11.9 mg/cm2 dried coating (i.e. about 80 microns). This coating suspension contains approximately 38% by weight on a dry basis of EUDRAGIT® L and is based in isopropyl alcohol and acetone with triethyl citrate as the acting plasticizer.
  • EXAMPLE 3
  • A wet granulation of 5-ASA (active ingredient), lactose, and povidone is blended with talc, magnesium stearate, sodium starch glycolate, and colloidal silicon dioxide. The blend is compressed into approximately 690 mg tablets containing 500 mg of the active ingredient on a standard pharmaceutical rotary tablet press.
  • An inner layer of an EUDRAGIT® S coating of 15.6 mg/cm2 dried coating (i.e. about 105 microns) is applied to the core tablets first by pouring a portion of the coating formula without pigments and then by spraying coating onto the tablets. The coating suspension sprayed onto the tablets contains approximately 62% by weight on a dry basis of Eudragit® S and is based in isopropyl alcohol and acetone with dibutylphthalate as the acting plasticizer.
  • An outer coating is applied immediately following the application of the inner coating or once the inner coating has cured. The outer coating layer is a hydroxpropyl methylcellulose coating applied to a thickness of about 100 microns of dried coating according to the following formula:
    Component Weight per Tablet
    Dri-Klear1 3.7 g
    White Chroma-Tone2   1 g
    Water  48 g

    1Dri-Klear is a mixture of hydroxypropyl methylcellulose, polyethylene glycol, hydroxypropyl cellulose, and silicon dioxide, manufactured by CHR Hansen.

    2White Chroma-Tone is a mixture of titanium dioxide and hydroxypropyl methylcellulose, manufactured by CHR Hansen.
  • EXAMPLE 4
  • Core tablets are manufactured to the following formula:
    Component Weight per Tablet
    Ketoprofen   2 mg
    Lactose 4.96 mg
    Starch 0.80 mg
    polyvinylpyrrolidone (PVP) 0.16 mg
    Magnesium stearate  0.8 mg
  • An inner layer of an EUDRAGIT® S coating about 20 microns is applied to the core tablets by spraying coating of the following formula:
    Component
    EUDRAGIT ® S100 3 g
    Diethyl phthalate 0.75 ml
    Silicone fluid 200/20CS 0.75 ml
    Methanol 25 parts 100 ml
    Dichloromehtane 75 parts
  • An outer coating layer is applied to the core tablet and inner coating layer. The outer coating layer is a hydroxpropyl methylcellulose coating applied to a thickness of about 150 microns of dried coating according to the following formula:
    Component
    Dri-Klear3 3.7 g
    White Chroma-Tone4   1 g
    Water  48 g

    3Dri-Klear is a mixture of hydroxypropyl methylcellulose, polyethylene glycol, hydroxypropyl cellulose, and silicon dioxide, manufactured by CHR Hansen.

    4White Chroma-Tone is a mixture of titanium dioxide and hydroxypropyl methylcellulose, manufactured by CHR Hansen.
  • EXAMPLE 5
  • Applied to the core tablets described in Example 4 is an inner layer of an aqueous EUDRAGIT® L 30 D-55 coating of about 70 microns dried coating of the following formula:
    Component
    EUDRAGIT ® L 30 D-55 260 g
    Talc  39 g
    Polyethylene glycol 6000  16 g
    Water 345 g
  • An outer coating layer is then applied as a hydroxpropyl methylcellulose coating to a thickness of about 50 microns of dried coating according to the following formula:
    Component
    Dri-Klear5 3.7 g
    White Chroma-Tone6   1 g
    Water  48 g

    5Dri-Klear is a mixture of hydroxypropyl methylcellulose. polyethylene glycol, hydroxypropyl cellulose, and silicon dioxide, manufactured by CHR Hansen.

    6White Chroma-Tone is a mixture of titanium dioxide and hydroxypropyl methylcellulose, manufactured by CHR Hansen.
  • EXAMPLE 6
  • The following formulation is encapsulated within soft or hard gelatin capsules:
    Component Weight per Tablet
    Insulin   20 i.u. (c.a. 1 mg)
    Sodium 5-methoxy salicyclate 150.0 mg
    PEG 4000  3.5 mg
    PEG 600 187.5 mg
    Capsule fill wt   342 mg
  • Thereafter, the capsule is coated. An inner layer of an EUDRAGIT® S coating is applied to the capsules by spraying coating of the following formula to a thickness of about 100 microns dried coating:
    Component
    EUDRAGIT ® S100  70 g
    Triethyl citrate  14 g
    Acetone 283 g
    Isopropyl Alcohol 483 g
  • Following the application of the inner coating, an outer coating layer of an EUDRAGIT® S and L mixture at a ratio of 2:3 of about 20 microns is applied to the tablets by spraying a coating of the following formula:
    Component Weight per Tablet
    EUDRAGIT ® L100  42 g
    EUDRAGIT ® S100  28 g
    Triethyl citrate  14 g
    Acetone 283 g
    Isopropyl Alcohol 483 g
  • While particular embodiments of the present invention have been described, it will be obvious to those skilled in the art that various changes and modifications of the present invention can be made without departing from the spirit and scope of the invention. It is intended to cover, in the appended claims, all such modifications that are within the scope of this invention.

Claims (20)

  1. 1-24. (canceled)
  2. 25. A pharmaceutical composition in a solid unit dosage form for oral administration in a human or lower animal comprising:
    a. a safe and effective amount of a therapeutically active agent;
    b. an inner coating layer selected from the group consisting of poly(methacrylic acid, methyl methacrylate) 1:2, poly(methacrylic acid, methyl methacrylate) 1:1, and mixtures thereof; and
    c. an outer coating layer having a minimum thickness from about 10 μm to about 200 μm, applied to the inner coating layer, said outer coating layer comprising a film coating material selected from the group consisting of cellulose ethers, methyl cellulose, ethylcellulose, carboxymethylcellulose, carboxymethylethylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, low viscosity hydroxypropyl cellulose, low viscosity hydroxypropyl methylcellulose, wax, carnauba wax, fatty alcohols, hydrogenated vegetable oils, zein, shellac, sucrose, Arabic gum, polyethylene glycol, polyvinylpyrolidone, gelatin, sodium alginate, dextrin, psyllium husk powder, cellulose acetate phthalate, cellulose acetate trimelliate, hydroxypropyl methylcellulose phthalate (HPMCP), cellulose propionate phthalate, cellulose acetate maleate, polyvinyl alcohol phthalate, hydroxypropyl methylcellulose acetate succinate (HPMCAS), hydroxypropyl methylcellulose hexahydrophthalate, and compatible mixtures thereof;
    wherein the solid unit dosage form has a total weight from about 550 mg to about 1500 mg; and
    wherein the inner coating layer and the outer coating layer contain no therapeutically active agent.
  3. 26. The composition of claim 25 wherein the inner coating layer is poly(methacrylic acid, methyl methacrylate) 1:2.
  4. 27. The composition of claim 25 wherein the film coating material is selected from the group consisting of cellulose ethers, methyl cellulose, ethylcellulose, carboxymethylcellulose, carboxymethylethylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, low viscosity hydroxypropyl cellulose, low viscosity hydroxypropyl methylcellulose, wax, carnauba wax, Arabic gum, polyethylene glycol, polyvinylpyrolidone, cellulose acetate phthalate, cellulose acetate trimelliate, hydroxypropyl methylcellulose phthalate (HPMCP), cellulose propionate phthalate, cellulose acetate maleate, polyvinyl alcohol phthalate, hydroxypropyl methylcellulose acetate succinate (HPMCAS), hydroxypropyl methylcellulose hexahydrophthalate, and compatible mixtures thereof.
  5. 28. The composition of claim 27 wherein the film coating material is selected from the group consisting of cellulose ethers, methyl cellulose, ethylcellulose, carboxymethylcellulose, carboxymethylethylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, and compatible mixtures thereof.
  6. 29. The composition of claim 28 wherein the film coating material is a mixture of hydroxypropyl cellulose and hydroxypropyl methylcellulose.
  7. 30. The composition of claim 25 wherein the therapeutically active agent is selected from the group consisting of laxatives, anti-diarrheals, nonsteroidal anti-inflammatory agents, glucocorticoids, antimicrobials, immunosuppressants, chemotherapeutics or anti-cancer drugs, peptides, proteins, cardiovascular drugs, psychotropic drugs, H2-blockers, antiasthmatic agents, and antihistamines.
  8. 31. The composition of claim 30 wherein the therapeutically active agent is a nonsteroidal anti-inflammatory agent.
  9. 32. The composition of claim 31 wherein the nonsteroidal anti-inflammatory agent is 5-amino salicylic acid or a pharmaceutically acceptable salt or ester thereof.
  10. 33. The composition of claim 32 wherein the 5-amino salicylic acid or pharmaceutically acceptable salt or ester thereof is present in an amount from about 700 mg to about 900 mg per solid unit dosage form.
  11. 34. The composition of claim 25 wherein the outer coating layer has a minimum thickness from about 30 μm to about 150 μm.
  12. 35. The composition of claim 25 wherein the total coating thickness of the inner and outer coating layers combined is from about 5 mg/cm2 to about 40 mg/cm2.
  13. 36. The composition of claim 35 wherein the total coating thickness is from about 10 mg/cm2 to about 15 mg/cm2.
  14. 37. The composition of claim 25 wherein the solid dosage form is coated by continuous spray methods wherein the outer coating layer is applied after the inner coating layer but before the inner coating layer is dried or cured.
  15. 38. The composition of claim 25 wherein the solid unit dosage form has a total weight from about 600 mg to about 1200 mg.
  16. 39. The composition of claim 38 wherein the solid unit dosage form has a total weight from about 750 mg to about 1000 mg.
  17. 40. The composition of claim 25 wherein the solid dosage form is a compressed tablet.
  18. 41. A method of consistent and reliable delivery and release of a therapeutically active agent to the desired region of delivery by orally administering the composition of claim 25.
  19. 42. A pharmaceutical composition in a solid unit dosage form for oral administration in a human or lower animal comprising:
    a. a safe and effective amount of 5-amino salicylic acid;
    b. an inner coating layer comprising poly(methacrylic acid, methyl methacrylate) 1:2; and
    c. an outer coating layer having a minimum thickness from about 10 μm to about 200 μm, applied to the inner coating layer, said outer coating layer comprising a mixture of hydroxypropyl cellulose and hydroxypropyl methylcellulose.
  20. 43. A method of consistent and reliable delivery and release of 5-amino salicylic acid to the desired region of delivery by orally administering the composition of claim 42.
US11096457 2000-11-20 2005-04-01 Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures Abandoned US20050181053A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US25212200 true 2000-11-20 2000-11-20
US09996555 US6893662B2 (en) 2000-11-20 2001-11-15 Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US11096457 US20050181053A1 (en) 2000-11-20 2005-04-01 Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11096457 US20050181053A1 (en) 2000-11-20 2005-04-01 Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09996555 Continuation US6893662B2 (en) 2000-11-20 2001-11-15 Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures

Publications (1)

Publication Number Publication Date
US20050181053A1 true true US20050181053A1 (en) 2005-08-18

Family

ID=22954700

Family Applications (4)

Application Number Title Priority Date Filing Date
US09996555 Active US6893662B2 (en) 2000-11-20 2001-11-15 Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US11070995 Active 2024-07-05 US8580302B2 (en) 2000-11-20 2005-03-03 Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US11096457 Abandoned US20050181053A1 (en) 2000-11-20 2005-04-01 Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US14051950 Active US9089492B2 (en) 2000-11-20 2013-10-11 Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09996555 Active US6893662B2 (en) 2000-11-20 2001-11-15 Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US11070995 Active 2024-07-05 US8580302B2 (en) 2000-11-20 2005-03-03 Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14051950 Active US9089492B2 (en) 2000-11-20 2013-10-11 Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures

Country Status (2)

Country Link
US (4) US6893662B2 (en)
CA (1) CA2359812C (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
US20070184111A1 (en) * 2006-02-03 2007-08-09 Pharmavite Llc Hybrid tablet
US20070292509A1 (en) * 2006-06-16 2007-12-20 Shin-Etsu Chemical Co., Ltd. Enteric coated granule and method for preparing the same
US8481565B2 (en) 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20140141075A1 (en) * 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
US8859005B2 (en) 2012-12-03 2014-10-14 Intercontinental Great Brands Llc Enteric delivery of functional ingredients suitable for hot comestible applications
US9089492B2 (en) 2000-11-20 2015-07-28 Warner Chilcott Company, Llc Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563522B2 (en) * 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US20020035071A1 (en) * 1997-07-08 2002-03-21 Josef Pitha Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites
US20060116330A1 (en) * 1997-07-08 2006-06-01 The Iams Company Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose
US8168170B2 (en) * 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
WO2004087113A1 (en) * 2003-04-04 2004-10-14 Ranbaxy Laboratories Limited Pharmaceutical compositions for colon specific delivery
US7737133B2 (en) 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
US7825106B2 (en) 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
EP1689398A2 (en) * 2003-11-26 2006-08-16 Novartis AG Compositions comprising organic compounds
US20050158294A1 (en) * 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US7785635B1 (en) * 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US20050152884A1 (en) * 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US8877178B2 (en) * 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US8894991B2 (en) * 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
WO2005074908A1 (en) 2004-02-06 2005-08-18 Borody, Thomas, Julius Use of aminosalicylates in diarrhoea-predominent irritable bowel syndrome
WO2005097082A1 (en) 2004-03-31 2005-10-20 Bpsi Holdings, Inc. Enteric coatings for orally ingestible substrates
KR20130028807A (en) * 2004-05-28 2013-03-19 샐릭스 파마슈티컬스 인코포레이티드 Prevention, treatment, and amelioration of radiation induced enteritis
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
EP2270131A1 (en) * 2005-05-31 2011-01-05 The Iams Company Feline probiotic lactobacilli
EP1885383B1 (en) * 2005-05-31 2016-09-21 IAMS Europe B.V. Feline probiotic bifidobacteria
US8557758B2 (en) 2005-06-07 2013-10-15 S.C. Johnson & Son, Inc. Devices for applying a colorant to a surface
US20070277849A1 (en) * 2006-06-06 2007-12-06 Shah Ketan N Method of neutralizing a stain on a surface
US7423002B2 (en) * 2005-06-07 2008-09-09 S.C. Johnson & Son, Inc. Method of neutralizing a stain on a surface
US7776108B2 (en) 2005-06-07 2010-08-17 S.C. Johnson & Son, Inc. Composition for application to a surface
US8846154B2 (en) 2005-06-07 2014-09-30 S.C. Johnson & Son, Inc. Carpet décor and setting solution compositions
US20100154146A1 (en) 2008-07-02 2010-06-24 S.C. Johnson & Son, Inc. Carpet decor and setting solution compositions
US7727289B2 (en) 2005-06-07 2010-06-01 S.C. Johnson & Son, Inc. Composition for application to a surface
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
CA2620091A1 (en) * 2005-08-24 2007-03-01 Salix Pharmaceuticals, Inc. Balsalazide formulations and manufacture and use thereof
US7964215B1 (en) 2006-01-24 2011-06-21 Emet Pharmaceuticals, LLC Delayed release dosage form
US20070253927A1 (en) * 2006-04-13 2007-11-01 Gwenaelle Jegou Cosmetic compositions comprising at least one dielectrophile monomer and at least one radical initiator
EP2050439B1 (en) * 2006-08-11 2016-11-23 Asahi Kasei Kabushiki Kaisha Process for production of spherical granule containing slightly water-soluble substance
CA2662428A1 (en) * 2006-09-13 2008-03-20 The Procter & Gamble Company Methods of treatment for ulcerative colitis
WO2008033125A1 (en) * 2006-09-13 2008-03-20 The Procter & Gamble Company Methods of treatment for ulcerative colitis using aminosalicylate
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
WO2008064192A3 (en) 2006-11-21 2008-09-04 Mcneil Ppc Inc Modified release analgesic suspensions
ES2551719T3 (en) 2007-02-01 2015-11-23 Iams Europe B.V. Method for decreasing inflammation and stress in a mammal using glucose antimetabolites, avocado or avocado extract
DK2079456T3 (en) 2007-04-04 2013-03-18 Sigmoid Pharma Ltd pharmaceutical cyclosporin
CA2687130C (en) 2007-05-07 2017-10-03 Evonik Roehm Gmbh Solid dosage forms comprising an enteric coating with accelerated drug release
US9833510B2 (en) * 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
US20090028944A1 (en) * 2007-07-16 2009-01-29 Balaji Sathurappan Pharmaceutical compositions comprising mesalamine
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
US8061269B2 (en) 2008-05-14 2011-11-22 S.C. Johnson & Son, Inc. Multilayer stencils for applying a design to a surface
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
WO2010080730A3 (en) * 2009-01-09 2010-11-25 Mayo Foundation For Medical Education And Research Methods and materials for delivering bile acids
ES2670808T3 (en) * 2009-08-28 2018-06-01 Hercules Llc Film coating composition from compounds in solid powder
US9539265B2 (en) 2013-03-15 2017-01-10 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
EP2953619A1 (en) 2013-03-15 2015-12-16 Warner Chilcott Company, LLC Mesalamine pharmaceutical composition with multiple dosage elements for reduced delivery variability

Citations (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211777A (en) * 1977-11-25 1980-07-08 Fisons Limited Compositions comprising a compound having sodium cromoglycate activity and aminosalicylic acid
US4312806A (en) * 1981-03-02 1982-01-26 G. D. Searle & Co. Method and compounds for treating inflammatory bowel disease
US4412992A (en) * 1980-07-21 1983-11-01 Biorex Laboratories Limited 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith
US4432966A (en) * 1979-12-10 1984-02-21 Roussel-Uclaf Compressed tablets for disintegration in the colon comprising an active ingredient containing nucleus coated with a first layer containing microcrystalline cellulose which is coated with an enteric organic polymer coating
US4496553A (en) * 1980-03-20 1985-01-29 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
US4537887A (en) * 1980-09-27 1985-08-27 Beecham Group Limited Pharmaceutical formulation
US4539198A (en) * 1983-07-07 1985-09-03 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range
US4540685A (en) * 1981-12-23 1985-09-10 Bauer Kurt H Process for the production of readily soluble 5-aminosalicylic acid preparations, compositions and methods of use
US4552899A (en) * 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4670112A (en) * 1984-11-22 1987-06-02 Farmaceutisk Laboratorium Ferring A/S Process for preparing p-amino phenols by electrolysis
US4678516A (en) * 1984-10-09 1987-07-07 The Dow Chemical Company Sustained release dosage form based on highly plasticized cellulose ether gels
US4780318A (en) * 1984-01-10 1988-10-25 Lejus Medical Aktiebolag Oral pharmaceutical composition
US4888179A (en) * 1987-01-15 1989-12-19 Lejus Medical Aktiebolag Diuretic composition
US4910021A (en) * 1985-11-29 1990-03-20 R. P. Scherer Corporation Targeted enternal delivery system
US5018621A (en) * 1990-04-16 1991-05-28 Connell Jr John J O Cylindrical container and dispenser for spherical objects
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US5053228A (en) * 1989-08-18 1991-10-01 W. R. Grace & Co.-Conn. Polymeric temperature sensitive drug carrier
US5068110A (en) * 1987-09-29 1991-11-26 Warner-Lambert Company Stabilization of enteric coated dosage form
US5082651A (en) * 1989-04-26 1992-01-21 Smith Kline & French Laboratories Limited Pharmaceutical compositions
US5171580A (en) * 1988-10-20 1992-12-15 Boehringer Ingelheim Italia S.P.A. Orally-pharmaceutical preparations with colon selective delivery
US5175003A (en) * 1990-04-06 1992-12-29 Biosytes Usa, Inc. Dual mechanism controlled release system for drug dosage forms
US5186943A (en) * 1988-08-22 1993-02-16 Ss Pharmaceutical Co., Ltd. Compressed-molded preparations
US5217720A (en) * 1990-07-10 1993-06-08 Shin-Etsu Chemical Co., Ltd. Coated solid medicament form having releasability in large intestine
US5270055A (en) * 1988-11-10 1993-12-14 Nordmark Arzneimittel Gmbh Solid pharmaceutical sustained-release form
US5294448A (en) * 1989-11-24 1994-03-15 British Technology Group Limited Delayed release formulations
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
US5342627A (en) * 1991-11-13 1994-08-30 Glaxo Canada Inc. Controlled release device
US5401512A (en) * 1991-02-22 1995-03-28 Rhodes; John Delayed release oral dosage forms for treatment of intestinal disorders
US5409711A (en) * 1990-04-17 1995-04-25 Eurand International Spa Pharmaceutical formulations
US5476667A (en) * 1990-10-16 1995-12-19 Kabi Pharmacia Ab Method for drug formulation and a pharmaceutical composition
US5482718A (en) * 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US5519014A (en) * 1990-10-22 1996-05-21 Borody; Thomas J. Treatment of non-inflammatory and non-infectious bowel disorders
US5536507A (en) * 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
US5541171A (en) * 1981-07-31 1996-07-30 Tillotts Pharma Ag Orally administrable pharmaceutical composition
US5540945A (en) * 1989-05-11 1996-07-30 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines
US5543155A (en) * 1993-12-09 1996-08-06 Egis Gyogyszergyar Rt. Diffusion-osmotic controlled drug-release pharmaceutical composition and process for preparing same
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5629012A (en) * 1991-06-17 1997-05-13 Farmaceutisk Laboratorium Ferring A/S Process for producing suppositories by compression and suppositories obtained by the process
US5654004A (en) * 1992-11-06 1997-08-05 Hisamitsu Pharmaceutical Co., Inc. Oral pharmaceutical preparation releasable in the lower digestive tract
US5656294A (en) * 1995-06-07 1997-08-12 Cibus Pharmaceutical, Inc. Colonic delivery of drugs
US5656296A (en) * 1992-04-29 1997-08-12 Warner-Lambert Company Dual control sustained release drug delivery systems and methods for preparing same
US5656290A (en) * 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5668123A (en) * 1995-09-01 1997-09-16 Synthelabo Method of maintaining remission from venous ulcers with sulphasalazine and its metabolite
US5681584A (en) * 1993-04-23 1997-10-28 Ciba-Geigy Corporation Controlled release drug delivery device
US5686105A (en) * 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5686106A (en) * 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
US5716648A (en) * 1993-06-08 1998-02-10 Farmaceutisk Laboratorium Ferring A/S Compositions for use in the regulation of subnormal pH values in the intestinal tract and for treatment of bowel diseases
US5731302A (en) * 1995-09-28 1998-03-24 Crinos Industria Farmacobiologica S.P.A. Stable aqueous suspensions of mesalazine
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US5811121A (en) * 1997-01-29 1998-09-22 Eastman Chemical Company PH-sensitive coatings based on cellulose acetoacetate
US5837277A (en) * 1992-06-04 1998-11-17 Smithkline Beecham Corporation Palatable pharmaceutical compositions
US5895663A (en) * 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
US5900252A (en) * 1990-04-17 1999-05-04 Eurand International S.P.A. Method for targeted and controlled release of drugs in the intestinal tract and more particularly in the colon
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5932249A (en) * 1993-09-23 1999-08-03 Dr. Falk Pharma Gmbh Budesonide pellets with a controlled released pattern and process for producing the same
US5985927A (en) * 1995-03-30 1999-11-16 Kreutz; Werner Medicaments for the selective treatment of tumor tissues
US6004581A (en) * 1995-12-21 1999-12-21 Farmaceutisk Laboratorium Ferring A/S Modified release oral pharmaceutical composition and method for the treatment of bowel diseases
US6068856A (en) * 1995-07-05 2000-05-30 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US6187756B1 (en) * 1996-09-05 2001-02-13 The Massachusetts Institute Of Technology Composition and methods for treatment of neurological disorders and neurodegenerative diseases
US6231888B1 (en) * 1996-01-18 2001-05-15 Perio Products Ltd. Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
US6326364B1 (en) * 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
US20010048965A1 (en) * 2000-06-06 2001-12-06 Cherukuri Subraman Rao Confectionery compositions
US20020034541A1 (en) * 2000-07-14 2002-03-21 Roberto Valducci Oral solid pharmaceutical formulations with pH-dependent multiphasic release
US6365185B1 (en) * 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US20020068088A1 (en) * 1996-08-15 2002-06-06 Peter Gruber Easy to swallow oral medicament composition
US20020155156A1 (en) * 2001-04-18 2002-10-24 Nostrum Pharmaceuticals, Inc. Novel coating for a sustained release pharmaceutical composition
US20020192282A1 (en) * 2000-03-17 2002-12-19 Thomas Beckert Multilayer pharmaceutical product for release in the colon
US6551620B2 (en) * 1997-07-30 2003-04-22 Dr. Falk Pharma Gmbh Pellet formulation for the treatment of the intestinal tract
US20030099711A1 (en) * 2001-08-29 2003-05-29 David Meadows Sustained release preparations
US20030138495A1 (en) * 2001-10-15 2003-07-24 Jepsen Svenn Kluver Method for the preparation of a pharmaceutical composition comprising 5-aminosalicylic acid for use in treatment of ulcerative colitis and crohn's disease
US20030152627A1 (en) * 2001-01-31 2003-08-14 Thomas Beckert Multi-particulate form of medicament, comprising at least two differently coated forms of pellet
US20030175349A1 (en) * 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
US6645528B1 (en) * 1999-05-27 2003-11-11 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US20040022844A1 (en) * 2001-10-30 2004-02-05 Steffen Hasenzahl Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
US20040096501A1 (en) * 2002-08-05 2004-05-20 Navin Vaya Novel drug delivery system
US20040096499A1 (en) * 2002-08-05 2004-05-20 Navin Vaya Novel dosage form
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US6773720B1 (en) * 1999-06-14 2004-08-10 Cosmo S.P.A. Mesalazine controlled release oral pharmaceutical compositions
US20040185097A1 (en) * 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
US6808616B2 (en) * 2000-06-15 2004-10-26 Noveon Ip Holdings Corp. Process for the preparation of 5-aminosalicyclic acid
US20040224017A1 (en) * 2003-03-14 2004-11-11 Nirmal Mulye Process for preparing sustained release tablets
US20040234601A1 (en) * 2001-10-09 2004-11-25 Valerie Legrand Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US20050079216A1 (en) * 2002-02-27 2005-04-14 Roehm Gmbh & Co. Kg Pharmaceutical dosage form and method for the production thereof
US20050090553A1 (en) * 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US6893662B2 (en) * 2000-11-20 2005-05-17 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US20050112201A1 (en) * 2003-09-19 2005-05-26 Penwest Pharmaceuticals Co. Delayed release dosage forms
US20050196459A1 (en) * 2003-11-25 2005-09-08 Flamel Technologies S.A. Carvedilol salts, anhydrates and/or solvate thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2512247A1 (en) 1975-03-20 1976-10-14 Thomae Gmbh Dr K Tablets contg. drying agents - for protection against moisture
EP0040590A3 (en) 1980-05-21 1983-01-12 Aktiebolaget Hässle A pharmaceutical preparation having improved release properties
JPH0420890B2 (en) 1981-12-23 1992-04-07 Eisai Co Ltd
JPS58213073A (en) 1982-06-07 1983-12-10 Masatoshi Yamada Solidification of oily substance
DE3907973A1 (en) 1989-03-11 1990-09-13 Merck Patent Gmbh Desiccant tablet
US5027797A (en) 1989-10-12 1991-07-02 Horace Bullard Apparatus for the movement of blood by external pressure
JPH072650A (en) 1993-06-18 1995-01-06 Tanabe Seiyaku Co Ltd Release part control type preparation
DE19511131A1 (en) 1995-03-27 1996-10-02 Basf Ag Mechanically stable solid drug formulations
US5631245A (en) 1995-06-06 1997-05-20 Biodynamics Pharmaceuticals, Inc. Method for medicating the inflammatory controlling system and adverse inflammatory reactions and for making compounds for treating the pathology of adverse inflammatory reactions
DE69615400D1 (en) 1995-12-21 2001-10-25 Farmaceutisk Lab Ferring As Va 5-asa-containing oral drug with modified release, as well as methods for treatment of bowel disease
CN1239425A (en) 1996-11-15 1999-12-22 普罗克特和甘保尔公司 Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
WO1998026767A3 (en) 1996-12-17 1998-09-03 Poli Ind Chimica Spa Site-specific controlled release dosage formulation for mesalamine
WO1998027967A1 (en) 1996-12-20 1998-07-02 Dumex-Alpharma A/S Release-controlled coated tablets
CA2220038A1 (en) 1998-01-05 1999-07-05 Amina Odidi Device for the delivery of high dose pharmaceutical, neutraceutical, agricultural, biological, and chemical substances
GB9810181D0 (en) 1998-05-13 1998-07-08 Smithkline Beecham Plc Novel formulations
WO2000044353A1 (en) 1999-01-29 2000-08-03 Losan Pharma Gmbh Pharmaceutical compositions
DE60005819T2 (en) 1999-06-14 2004-05-06 Cosmo S.P.A. A taste masked oral pharmaceutical compositions with controlled release
WO2001066094A1 (en) 2000-03-07 2001-09-13 Pharmatec International S.R.L. Controlled release oral solid forms containing mesalazine as active agent
DE10013030A1 (en) 2000-03-17 2001-09-20 Roehm Gmbh Formulation for treating ulcerative colitis, comprising active agent, e.g. 5-aminosalicylic acid or prednisone, coated with acrylic copolymer to provide delayed release at high pH in the colon
DE60106889T2 (en) 2000-03-31 2006-03-23 Watson Laboratories, Inc., Salt Lake City A process for making a tablet with controlled release with the use of a pore-forming agent in the coating
WO2001091716A1 (en) 2000-05-30 2001-12-06 Add Advanced Drug Delivery Technologies Ag Peroral therapeutic system comprising glipizide
DE50013843D1 (en) 2000-08-29 2007-01-18 Mepha Ag Drugs for treatment of bowel disease
DE60133319D1 (en) 2001-11-23 2008-04-30 Procter & Gamble Multiple beschichete pharmaceutical dosage form
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
FR2837100B1 (en) 2002-03-18 2004-07-23 Flamel Tech Sa Tablets has bases modified release microcapsules
CA2491355A1 (en) 2002-07-05 2004-01-15 Temrel Limited Controlled release compositions comprising coated pellets having non-uniform coating thicknesses
DE10250543A1 (en) 2002-10-29 2004-05-19 Röhm GmbH & Co. KG Multilayer pharmaceutical form
DE10304403A1 (en) 2003-01-28 2004-08-05 Röhm GmbH & Co. KG A method for preparing an oral dosage form with immediate disintegration and drug release
WO2004087113A1 (en) 2003-04-04 2004-10-14 Ranbaxy Laboratories Limited Pharmaceutical compositions for colon specific delivery
US7825106B2 (en) 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
CA2539799A1 (en) 2003-09-22 2005-03-31 Nisshin Kyorin Pharmaceutical Co., Ltd. 5-aminosalicylic acid solid preparation improved in discoloration and method of storing the same
WO2005030173A1 (en) 2003-09-25 2005-04-07 Ranbaxy Laboratories Limited Colon-specific drug delivery using interpolymer complexations
EP1547601A1 (en) 2003-12-23 2005-06-29 Ferring B.V. Coating method
FR2872044B1 (en) 2004-06-28 2007-06-29 Flamel Technologies Sa pharmaceutical formulation of antibiotic base in microcapsular form
DE602005013098D1 (en) 2004-09-01 2009-04-16 Procter & Gamble Compositions containing 5-amino-2-hydroxybenzoic acid and a reducing sugar
US20080020041A1 (en) 2004-10-19 2008-01-24 Ayres James W Enteric Coated Compositions that Release Active Ingredient(s) in Gastric Fluid and Intestinal Fluid
KR100912307B1 (en) 2004-10-21 2009-08-14 유니버시티 오브 아이오와 리써치 파운데이션 In situ controlled release drug delivery system
US20060141054A1 (en) 2004-10-25 2006-06-29 Thomas Piccariello Metal coordinated compositions
CN102631289B (en) 2004-10-28 2016-05-04 潘特克股份公司 Fast disintegrating solid dosage form comprising a high porosity and a process for producing a powder preparation and the lyophilization step
FR2878159B1 (en) 2004-11-24 2008-10-17 Flamel Technologies Sa Oral drug has modified release of at least one active ingredient in the form multimicrocapsular
US7691364B2 (en) 2005-01-28 2010-04-06 Bezwada Biomedical, Llc Functionalized drugs and polymers derived therefrom
US9149439B2 (en) 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
EP1883614A4 (en) 2005-05-23 2010-04-14 Nicox Sa Organic nitric oxide enhancing salts of nonsteroidal antiinflammatory compounds, compositions and methods of use
US20070059368A1 (en) 2005-05-31 2007-03-15 Cherukuri S R Modified release formulations of anti-irritability drugs
US20090017110A1 (en) 2005-05-31 2009-01-15 Capricorn Pharma Inc. Modified release formulations of anti-irritability drugs
US20060292225A1 (en) 2005-06-24 2006-12-28 Felix Arthur M Water soluble analgesic formulations and methods for production
US8920837B2 (en) 2005-07-01 2014-12-30 Rubicon Research Private Limited Sustained release dosage form
WO2007052289B1 (en) 2005-07-22 2008-02-28 Rubicon Res Pvt Ltd Novel dispersible tablet composition
WO2007020508A1 (en) 2005-08-12 2007-02-22 Ferring International Center S.A. Method and device for dividing granules
WO2007019888A3 (en) 2005-08-12 2007-07-12 Ctg Pharma S R L Therapeutic compositions containing mesalamine and a co-agent for treating colon diseases
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US20080248107A1 (en) 2005-08-24 2008-10-09 Rubicon Research Pvt. Ltd. Controlled Release Formulation
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US9603941B2 (en) 2006-01-24 2017-03-28 Minghui Chai Method of preparing dendritic drugs
EP1976486A1 (en) 2006-01-27 2008-10-08 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A method of producing porous microparticles
WO2007127488A1 (en) 2006-04-27 2007-11-08 Shenoy Narmada R Compositions and methods for treating or preventing diseases of body passageways
CN101522174A (en) 2006-05-10 2009-09-02 赢创德固赛有限责任公司 Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions
WO2008008120A1 (en) 2006-07-14 2008-01-17 Fmc Corporation Solid form
KR20090027734A (en) 2006-07-27 2009-03-17 (주)아모레퍼시픽 Process for preparing powder comprising nanoparticles of sparingly soluble drug
WO2008033125A1 (en) 2006-09-13 2008-03-20 The Procter & Gamble Company Methods of treatment for ulcerative colitis using aminosalicylate
CA2662428A1 (en) 2006-09-13 2008-03-20 The Procter & Gamble Company Methods of treatment for ulcerative colitis
US20080081070A1 (en) 2006-09-15 2008-04-03 Auriga Laboratories, Inc. Pharmaceutical formulation with enhanced solubility for the delivery of corticosteroids
US8921344B2 (en) 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
WO2008056200A1 (en) 2006-11-10 2008-05-15 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of simethicone
RU2485945C2 (en) 2006-11-17 2013-06-27 Шир Девелопмент Инк. Method of treating inflammatory intestinal diseases
WO2008068584A3 (en) 2006-12-05 2009-02-12 Univ Witwatersrand Johannesbur A heterogeneously configured multiparticulate gastrointestinal drug delivery system
WO2008085484A3 (en) 2006-12-28 2008-09-18 Jacobus Pharmaceutical Company Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
DE102007009242A1 (en) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets with enteric drug Matix
DE102007009243A1 (en) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets with an active matrix and a polymer coating, and a process for the preparation of the pellets
ES2384195T3 (en) 2007-02-28 2012-07-02 Giuliani International Limited PPAR-gamma agonists for the induction of cationic antimicrobial peptide expression as immunoprotective stimulants
US20080286343A1 (en) 2007-05-16 2008-11-20 Dzenana Cengic Solid form
US20080311162A1 (en) 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
WO2008140459A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
US20080286344A1 (en) 2007-05-16 2008-11-20 Olivia Darmuzey Solid form
WO2008140461A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
WO2008140460A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
US8217083B2 (en) 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
US7541384B2 (en) 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
US8637080B2 (en) 2007-06-28 2014-01-28 Osmotica Kereskedelmi és Szolgáltató, KFT Rupturing controlled release device comprising a subcoat
US8974825B2 (en) 2007-07-06 2015-03-10 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
US20090028944A1 (en) 2007-07-16 2009-01-29 Balaji Sathurappan Pharmaceutical compositions comprising mesalamine
US20090036414A1 (en) 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
WO2009040818A9 (en) 2007-09-25 2010-05-20 Solubest Ltd Compositions comprising lipophilic active compounds and method for their preparation
WO2009047801A1 (en) 2007-10-10 2009-04-16 Lupin Limited Therapeutic combinations and compositions for the treatment of gastrointestinal disorders
WO2009047802A3 (en) 2007-10-10 2009-09-24 Lupin Limited Novel colon targeted modified release bioadhesive formulation of 5-amino salicylic acid or its salts and metabolites thereof
WO2009148470A1 (en) 2007-10-25 2009-12-10 The Board Of Trustees Of Southern Illinois University Methods for diagnosing bowel disease
WO2009078872A1 (en) 2007-12-18 2009-06-25 Soluprin Pharmaceuticals, Inc. Orally disintegrating water soluble analgesic formulations and methods for production thereof
US20090162434A1 (en) 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
EP2222291B1 (en) 2007-12-24 2012-03-21 Giuliani International Limited Compounds for the selective treatment of the intestinal immuno-inflammatory component of the celiac disease
US20090169622A1 (en) 2007-12-27 2009-07-02 Roxane Laboratories, Inc. Delayed-release oral pharmaceutical composition for treatment of colonic disorders
EP2249808A2 (en) 2008-01-11 2010-11-17 Cipla Limited Solid pharmaceutical dosage form
EP2133071A1 (en) 2008-06-09 2009-12-16 Université de la Mériterranée Process for making gastroretentive dosage forms
WO2009150530A3 (en) 2008-06-11 2010-10-28 Ferring International Center Sa Pharmaceutical composition suitable for use as foam comprising 5'-aminosalicylic acid and silicone oil
EP2135601A1 (en) 2008-06-20 2009-12-23 Capsulution Nanoscience AG Stabilization of amorphous drugs using sponge-like carrier matrices
WO2009158384A1 (en) 2008-06-27 2009-12-30 The Procter & Gamble Company Methods and kits for the treatment inhibition, and maintenance of gastrointestinal disorders
WO2010005521A1 (en) 2008-06-30 2010-01-14 Bltn, Llc Azelaic acid ester compositions and methods for diagnosing and treating tissue conditions using azelaic acid ester compositions and proteinaceous biomarkers

Patent Citations (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211777A (en) * 1977-11-25 1980-07-08 Fisons Limited Compositions comprising a compound having sodium cromoglycate activity and aminosalicylic acid
US4432966A (en) * 1979-12-10 1984-02-21 Roussel-Uclaf Compressed tablets for disintegration in the colon comprising an active ingredient containing nucleus coated with a first layer containing microcrystalline cellulose which is coated with an enteric organic polymer coating
US4880794A (en) * 1980-03-20 1989-11-14 Soren Halskov Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration
US4496553B1 (en) * 1980-03-20 1988-06-28
US4496553A (en) * 1980-03-20 1985-01-29 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
US4980173A (en) * 1980-03-20 1990-12-25 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
US5013727A (en) * 1980-03-20 1991-05-07 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
US4412992A (en) * 1980-07-21 1983-11-01 Biorex Laboratories Limited 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith
US4537887A (en) * 1980-09-27 1985-08-27 Beecham Group Limited Pharmaceutical formulation
US4312806A (en) * 1981-03-02 1982-01-26 G. D. Searle & Co. Method and compounds for treating inflammatory bowel disease
US5541170A (en) * 1981-07-31 1996-07-30 Tillotts Pharma Ag Orally administrable pharmaceutical compositions
US5541171A (en) * 1981-07-31 1996-07-30 Tillotts Pharma Ag Orally administrable pharmaceutical composition
US4540685A (en) * 1981-12-23 1985-09-10 Bauer Kurt H Process for the production of readily soluble 5-aminosalicylic acid preparations, compositions and methods of use
US4632921A (en) * 1981-12-23 1986-12-30 Bauer Kurt H Process for the production of readily soluble 5-aminosalicylic acid preparations
US4539198A (en) * 1983-07-07 1985-09-03 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range
US4780318A (en) * 1984-01-10 1988-10-25 Lejus Medical Aktiebolag Oral pharmaceutical composition
US4552899A (en) * 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4552899B1 (en) * 1984-04-09 1992-10-20 Analgesic Associates
US4678516A (en) * 1984-10-09 1987-07-07 The Dow Chemical Company Sustained release dosage form based on highly plasticized cellulose ether gels
US4670112A (en) * 1984-11-22 1987-06-02 Farmaceutisk Laboratorium Ferring A/S Process for preparing p-amino phenols by electrolysis
US4910021A (en) * 1985-11-29 1990-03-20 R. P. Scherer Corporation Targeted enternal delivery system
US4888179A (en) * 1987-01-15 1989-12-19 Lejus Medical Aktiebolag Diuretic composition
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US5068110A (en) * 1987-09-29 1991-11-26 Warner-Lambert Company Stabilization of enteric coated dosage form
US5186943A (en) * 1988-08-22 1993-02-16 Ss Pharmaceutical Co., Ltd. Compressed-molded preparations
US5171580A (en) * 1988-10-20 1992-12-15 Boehringer Ingelheim Italia S.P.A. Orally-pharmaceutical preparations with colon selective delivery
US5270055A (en) * 1988-11-10 1993-12-14 Nordmark Arzneimittel Gmbh Solid pharmaceutical sustained-release form
US5082651A (en) * 1989-04-26 1992-01-21 Smith Kline & French Laboratories Limited Pharmaceutical compositions
US5540945A (en) * 1989-05-11 1996-07-30 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines
US5053228A (en) * 1989-08-18 1991-10-01 W. R. Grace & Co.-Conn. Polymeric temperature sensitive drug carrier
US5294448A (en) * 1989-11-24 1994-03-15 British Technology Group Limited Delayed release formulations
US5175003A (en) * 1990-04-06 1992-12-29 Biosytes Usa, Inc. Dual mechanism controlled release system for drug dosage forms
US5018621A (en) * 1990-04-16 1991-05-28 Connell Jr John J O Cylindrical container and dispenser for spherical objects
US5900252A (en) * 1990-04-17 1999-05-04 Eurand International S.P.A. Method for targeted and controlled release of drugs in the intestinal tract and more particularly in the colon
US5409711A (en) * 1990-04-17 1995-04-25 Eurand International Spa Pharmaceutical formulations
US5217720A (en) * 1990-07-10 1993-06-08 Shin-Etsu Chemical Co., Ltd. Coated solid medicament form having releasability in large intestine
US5476667A (en) * 1990-10-16 1995-12-19 Kabi Pharmacia Ab Method for drug formulation and a pharmaceutical composition
US5519014A (en) * 1990-10-22 1996-05-21 Borody; Thomas J. Treatment of non-inflammatory and non-infectious bowel disorders
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
US5401512A (en) * 1991-02-22 1995-03-28 Rhodes; John Delayed release oral dosage forms for treatment of intestinal disorders
US5629012A (en) * 1991-06-17 1997-05-13 Farmaceutisk Laboratorium Ferring A/S Process for producing suppositories by compression and suppositories obtained by the process
US5342627A (en) * 1991-11-13 1994-08-30 Glaxo Canada Inc. Controlled release device
US5639476A (en) * 1992-01-27 1997-06-17 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5656296A (en) * 1992-04-29 1997-08-12 Warner-Lambert Company Dual control sustained release drug delivery systems and methods for preparing same
US5837277A (en) * 1992-06-04 1998-11-17 Smithkline Beecham Corporation Palatable pharmaceutical compositions
US20050090553A1 (en) * 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US5654004A (en) * 1992-11-06 1997-08-05 Hisamitsu Pharmaceutical Co., Inc. Oral pharmaceutical preparation releasable in the lower digestive tract
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5656290A (en) * 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5681584A (en) * 1993-04-23 1997-10-28 Ciba-Geigy Corporation Controlled release drug delivery device
US5716648A (en) * 1993-06-08 1998-02-10 Farmaceutisk Laboratorium Ferring A/S Compositions for use in the regulation of subnormal pH values in the intestinal tract and for treatment of bowel diseases
US5932249A (en) * 1993-09-23 1999-08-03 Dr. Falk Pharma Gmbh Budesonide pellets with a controlled released pattern and process for producing the same
US5686105A (en) * 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US5543155A (en) * 1993-12-09 1996-08-06 Egis Gyogyszergyar Rt. Diffusion-osmotic controlled drug-release pharmaceutical composition and process for preparing same
US5482718A (en) * 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
US5536507A (en) * 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
US5985927A (en) * 1995-03-30 1999-11-16 Kreutz; Werner Medicaments for the selective treatment of tumor tissues
US5686106A (en) * 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
US5656294A (en) * 1995-06-07 1997-08-12 Cibus Pharmaceutical, Inc. Colonic delivery of drugs
US6068856A (en) * 1995-07-05 2000-05-30 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US5668123A (en) * 1995-09-01 1997-09-16 Synthelabo Method of maintaining remission from venous ulcers with sulphasalazine and its metabolite
US5731302A (en) * 1995-09-28 1998-03-24 Crinos Industria Farmacobiologica S.P.A. Stable aqueous suspensions of mesalazine
US6004581A (en) * 1995-12-21 1999-12-21 Farmaceutisk Laboratorium Ferring A/S Modified release oral pharmaceutical composition and method for the treatment of bowel diseases
US6231888B1 (en) * 1996-01-18 2001-05-15 Perio Products Ltd. Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
US20020068088A1 (en) * 1996-08-15 2002-06-06 Peter Gruber Easy to swallow oral medicament composition
US6709678B2 (en) * 1996-08-15 2004-03-23 Losan Pharma Gmbh Easy to swallow oral medicament composition
US6187756B1 (en) * 1996-09-05 2001-02-13 The Massachusetts Institute Of Technology Composition and methods for treatment of neurological disorders and neurodegenerative diseases
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US5811121A (en) * 1997-01-29 1998-09-22 Eastman Chemical Company PH-sensitive coatings based on cellulose acetoacetate
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
US6551620B2 (en) * 1997-07-30 2003-04-22 Dr. Falk Pharma Gmbh Pellet formulation for the treatment of the intestinal tract
US5895663A (en) * 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
US6365185B1 (en) * 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
US6326364B1 (en) * 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6645528B1 (en) * 1999-05-27 2003-11-11 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6932983B1 (en) * 1999-05-27 2005-08-23 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6773720B1 (en) * 1999-06-14 2004-08-10 Cosmo S.P.A. Mesalazine controlled release oral pharmaceutical compositions
US20020192282A1 (en) * 2000-03-17 2002-12-19 Thomas Beckert Multilayer pharmaceutical product for release in the colon
US6632454B2 (en) * 2000-03-17 2003-10-14 Roehm Gmbh & Co. Kg Multilayer pharmaceutical product for release in the colon
US20010048965A1 (en) * 2000-06-06 2001-12-06 Cherukuri Subraman Rao Confectionery compositions
US6808616B2 (en) * 2000-06-15 2004-10-26 Noveon Ip Holdings Corp. Process for the preparation of 5-aminosalicyclic acid
US20020034541A1 (en) * 2000-07-14 2002-03-21 Roberto Valducci Oral solid pharmaceutical formulations with pH-dependent multiphasic release
US6893662B2 (en) * 2000-11-20 2005-05-17 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US20030175349A1 (en) * 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
US20030152627A1 (en) * 2001-01-31 2003-08-14 Thomas Beckert Multi-particulate form of medicament, comprising at least two differently coated forms of pellet
US20020155156A1 (en) * 2001-04-18 2002-10-24 Nostrum Pharmaceuticals, Inc. Novel coating for a sustained release pharmaceutical composition
US20030099711A1 (en) * 2001-08-29 2003-05-29 David Meadows Sustained release preparations
US20040234601A1 (en) * 2001-10-09 2004-11-25 Valerie Legrand Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US20030138495A1 (en) * 2001-10-15 2003-07-24 Jepsen Svenn Kluver Method for the preparation of a pharmaceutical composition comprising 5-aminosalicylic acid for use in treatment of ulcerative colitis and crohn's disease
US20040022844A1 (en) * 2001-10-30 2004-02-05 Steffen Hasenzahl Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
US20050079216A1 (en) * 2002-02-27 2005-04-14 Roehm Gmbh & Co. Kg Pharmaceutical dosage form and method for the production thereof
US20040096501A1 (en) * 2002-08-05 2004-05-20 Navin Vaya Novel drug delivery system
US20040096499A1 (en) * 2002-08-05 2004-05-20 Navin Vaya Novel dosage form
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US20040185097A1 (en) * 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
US20040224017A1 (en) * 2003-03-14 2004-11-11 Nirmal Mulye Process for preparing sustained release tablets
US20050112201A1 (en) * 2003-09-19 2005-05-26 Penwest Pharmaceuticals Co. Delayed release dosage forms
US20050196459A1 (en) * 2003-11-25 2005-09-08 Flamel Technologies S.A. Carvedilol salts, anhydrates and/or solvate thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9089492B2 (en) 2000-11-20 2015-07-28 Warner Chilcott Company, Llc Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
US8481565B2 (en) 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US8507527B2 (en) 2004-12-27 2013-08-13 Eisai R & D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20070184111A1 (en) * 2006-02-03 2007-08-09 Pharmavite Llc Hybrid tablet
US20070292509A1 (en) * 2006-06-16 2007-12-20 Shin-Etsu Chemical Co., Ltd. Enteric coated granule and method for preparing the same
US9095513B2 (en) 2006-06-16 2015-08-04 Shin-Etsu Chemical Co., Ltd. Enteric coated granule and method for preparing the same
US20140141075A1 (en) * 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
US8859005B2 (en) 2012-12-03 2014-10-14 Intercontinental Great Brands Llc Enteric delivery of functional ingredients suitable for hot comestible applications

Also Published As

Publication number Publication date Type
US9089492B2 (en) 2015-07-28 grant
CA2359812C (en) 2004-02-10 grant
US20020098235A1 (en) 2002-07-25 application
US8580302B2 (en) 2013-11-12 grant
CA2359812A1 (en) 2002-05-20 application
US6893662B2 (en) 2005-05-17 grant
US20140093576A1 (en) 2014-04-03 application
US20050169996A1 (en) 2005-08-04 application

Similar Documents

Publication Publication Date Title
US6531152B1 (en) Immediate release gastrointestinal drug delivery system
US6309666B1 (en) Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract
US5489436A (en) Taste mask coatings for preparation of chewable pharmaceutical tablets
US6027748A (en) Pharmaceutical tablet, completely coated, for controlled release of active principles that present problems of bio-availability linked to gastro-intestinal absorption
US6245351B1 (en) Controlled-release composition
US4728512A (en) Formulations providing three distinct releases
US6838093B2 (en) System for osmotic delivery of pharmaceutically active agents
US5631022A (en) Picosulfate dosage form
US5277916A (en) Tetracycline dosage form
US7048945B2 (en) Timed pulsatile drug delivery systems
US4904474A (en) Delivery of drug to colon by oral disage form
US4716041A (en) Diffusion coated multiple-units dosage form
US6346269B1 (en) Method for preparing an oral formulation containing acid-sensitive drugs and oral formulation made thereby
US6322819B1 (en) Oral pulsed dose drug delivery system
US20030091623A1 (en) Solid oral dosage form containing an enhancer
US20040052844A1 (en) Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins
US5891474A (en) Time-specific controlled release dosage formulations and method of preparing same
US5188836A (en) Sustained release formulations
US6479075B1 (en) Pharmaceutical formulations for acid labile substances
US4794001A (en) Formulations providing three distinct releases
US4904476A (en) Formulations providing three distinct releases
US6174548B1 (en) Omeprazole formulation
US20050249807A1 (en) Pharmaceutical formulations
US20010007680A1 (en) Use of a film coating as taste-masking coating of oral dosage forms
US5395628A (en) Controlled release succinic acid microcapsules coated with aqueous acrylics

Legal Events

Date Code Title Description
AS Assignment

Owner name: THE PROCTER & GAMBLE COMPANY, OHIO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DITTMAR, GREGORY PAUL;AMANTE, JOSEPH MICHAEL;CRONK, TONY RYAN;AND OTHERS;REEL/FRAME:023121/0943;SIGNING DATES FROM 20011031 TO 20011112

AS Assignment

Owner name: CREDIT SUISSE, CAYMAN ISLANDS BRANCH, AS ADMINISTR

Free format text: SECURITY AGREEMENT;ASSIGNOR:WARNER CHILCOTT COMPANY, LLC;REEL/FRAME:023456/0052

Effective date: 20091030

AS Assignment

Owner name: WARNER CHILCOTT COMPANY, LLC,PUERTO RICO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PROCTER & GAMBLE COMPANY, THE;REEL/FRAME:023796/0417

Effective date: 20091030

Owner name: WARNER CHILCOTT COMPANY, LLC, PUERTO RICO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PROCTER & GAMBLE COMPANY, THE;REEL/FRAME:023796/0417

Effective date: 20091030

AS Assignment

Owner name: WARNER CHILCOTT COMPANY LLC, PUERTO RICO

Free format text: RELEASE - REEL 023456, FRAME 0052;ASSIGNOR:CREDIT SUISSSE AG, CAYMAN ISLANDS BRANCH, AS ADMINISTRATIVE AGENT;REEL/FRAME:026042/0046

Effective date: 20110317

AS Assignment

Owner name: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT, NO

Free format text: SECURITY AGREEMENT;ASSIGNOR:WARNER CHILCOTT COMPANY LLC;REEL/FRAME:026064/0607

Effective date: 20110317

AS Assignment

Owner name: WARNER CHILCOTT COMPANY, LLC, NEW JERSEY

Free format text: RELEASE OF SECURITY INTEREST;ASSIGNOR:BANK OF AMERICA, N.A., AS COLLATERAL AGENT;REEL/FRAME:031531/0538

Effective date: 20131001

AS Assignment

Owner name: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED, IR

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WARNER CHILCOTT COMPANY, LLC;REEL/FRAME:040183/0129

Effective date: 20151231

AS Assignment

Owner name: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED, IR

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE US PATENT NO. 8,050,873 PREVIOUSLY RECORDED ON REEL 040183 FRAME 0129. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNOR:WARNER CHILCOTT COMPANY, LLC;REEL/FRAME:045417/0593

Effective date: 20151231